Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Arrhythmias

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 49 articles: HTML format

Single Articles

December 2025
1. TAMIRISA KP, Sanchez JE, La Fazia VM, Gianni C, et al
   Pulsed field ablation-related hemoglobinuria and acute kidney injury: Insights and strategies for effective management.
   Am Heart J. 2025;290:339-346.
   PubMed     Abstract available
   
   
   October 2025
2. KIM KS, Belley-Cote EP, Walsh M, Wang A, et al
   Left atrial appendage occlusion study III-Kidney substudy.
   Am Heart J. 2025;288:90-100.
   PubMed     Abstract available
   
   
   September 2025
3. LANDMESSER U, Skurk C, Kirchhof P, Lewalter T, et al
   Catheter-based left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial.
   Am Heart J. 2025 Sep 12:S0002-8703(25)00326-6. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   August 2025
4. HARRINGTON J, Reddy RK, Carnicelli A, Wilson L, et al
   Medicare Coverage Gap Status, Adherence to Oral Anticoagulation, and Stroke Rates in Patients with Atrial Fibrillation.
   Am Heart J. 2025 Aug 6:S0002-8703(25)00290-X. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   July 2025
5. WIJESURENDRA R, Pessoa-Amorim G, Buck G, Harper C, et al
   Active Monitoring for AtriaL FIbrillation (AMALFI): rationale, protocol, and pilot for a pragmatic, randomized, controlled trial of remote screening for asymptomatic atrial fibrillation.
   Am Heart J. 2025 Jul 16:S0002-8703(25)00213-3. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
6. HAN J, Qi W, Yuan S, Liu H, et al
   Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design and study protocol for a multicenter randomized controlled trial (SAFE-AF).
   Am Heart J. 2025 Jul 15:S0002-8703(25)00220-0. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   June 2025
7. HIJAZI Z, Wallentin L, Arheden H, Bjorkenheim A, et al
   Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation: Short title: The ABC AF-study design.
   Am Heart J. 2025 Jun 23:S0002-8703(25)00200-5. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
8. MAGNANI JW, Lalama CM, Abebe KZ, Ma DF, et al
   A Mobile Relational Agent to Enhance Atrial Fibrillation Self-care: Primary and secondary outcomes of a Randomized Controlled Trial.
   Am Heart J. 2025 Jun 20:S0002-8703(25)00198-X. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
9. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
   Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
   Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
10. DILK P, Uhe T, Forkmann M, Eckardt L, et al
    Pulmonary Vein Isolation versus SHAM-pulmonary vein isolation for symptomatic relief in patients with Atrial Fibrillation - design and rationale of the PVI-SHAM-AF trial.
    Am Heart J. 2025 Jun 11:S0002-8703(25)00192-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
11. ZIMERMAN A, Dal Forno A, Rohde LE, Ternes CMP, et al
    Conduction System Pacing vs. Biventricular Resynchronization in Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block: Rationale and Design of the PhysioSync-HF Trial.
    Am Heart J. 2025 Jun 3:S0002-8703(25)00191-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    May 2025
12. BARUA S, Upadhyay D, Surapaneni A, Grams M, et al
    Fitbit-measured physical activity is inversely associated with incident atrial fibrillation among All of Us participants.
    Am Heart J. 2025 May 14:S0002-8703(25)00160-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    April 2025
13. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
14. BOCKUS L, Kassar A, Chahine Y, Chamoun N, et al
    Atrial fibrillation is associated with higher oxygen extraction in the human heart.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00129-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
15. GOSVIG K, Goller J, Hansson NH, Brandes A, et al
    Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00131-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
16. BODE D, Parwani AS
    Cardiac Oxygen Consumption in Atrial Fibrillation: A Heart Out of Breath.
    Am Heart J. 2025 Apr 14:S0002-8703(25)00130-9. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    February 2025
17. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
18. ASHBURNER JM, Tack RWP, Khurshid S, Turner AC, et al
    Impact of a Clinical Atrial Fibrillation Risk Estimation Tool on Cardiac Rhythm Monitor Utilization Following Acute Ischemic Stroke: A Pre-Post Clinical Trial.
    Am Heart J. 2025 Feb 18:S0002-8703(25)00039-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    December 2024
19. HAVERS-BORGERSEN E, Jons C, Butt JH, Schmidt MR, et al
    Arrhythmias in congenital heart disease: A nationwide cohort study.
    Am Heart J. 2024;278:139-149.
    PubMed     Abstract available
    
    
    November 2024
20. FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al
    Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
    Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    October 2024
21. POKORNEY SD, Nemeth H, Chiswell K, Albert C, et al
    Design and Rationale of a Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation - The CHANGE AFIB Study.
    Am Heart J. 2024 Oct 16:S0002-8703(24)00263-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
22. WHITLOCK RP, McCarthy PM, Gerdisch MW, Ramlawi B, et al
    The left atrial appendage exclusion for prophylactic stroke reduction (leaaps) trial: rationale and design.
    Am Heart J. 2024 Oct 10:S0002-8703(24)00268-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    September 2024
23. TAN A, Sreedhara SK, Russo M, Singer DE, et al
    Assessing Methods to Ascertain Persistence and Adherence of Oral Anticoagulants in Patients with Atrial Fibrillation.
    Am Heart J. 2024 Sep 18:S0002-8703(24)00237-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
24. LITWIN SE, Komtebedde J, Borlaug BA, Kaye DM, et al
    Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials.
    Am Heart J. 2024 Sep 3:S0002-8703(24)00216-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    August 2024
25. JAIN SS, Mahaffey KW, Pieper KS, Shimizu W, et al
    Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
    Am Heart J. 2024 Aug 27:S0002-8703(24)00206-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
26. SANNA GD, Erre GL, Cameli M, Guerra F, et al
    Association of sex with in-hospital management and outcomes of patients with heart failure: data from the REAL-HF registry: The impact of sex in patients hospitalized for heart failure.
    Am Heart J. 2024 Aug 27:S0002-8703(24)00221-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
27. JIANG C, Wang Z, Du X, Wang Y, et al
    Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial.
    Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
28. REIFFEL JA
    Comparative effectiveness of monitoring duration for detection of potential or suspected arrhythmias.
    Am Heart J. 2024;274:113-114.
    PubMed    
    
    
    April 2024
29. COX J, Hamilton L, Thabane L, Foster G, et al
    Computerized Clinical Decision Support to Improve Stroke Prevention Therapy in Primary Care Management of Atrial Fibrillation: A Cluster Randomized Trial.
    Am Heart J. 2024 Apr 27:S0002-8703(24)00103-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
30. ELKHOLEY K, Asad ZUA, Shehata E, Mustafina I, et al
    Association between atrial fibrillation and heart failure patient reported outcomes across the ejection fraction spectrum.
    Am Heart J. 2024 Apr 27:S0002-8703(24)00104-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
31. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
    A Randomized Clinical Trial of Catheter Ablation and Antiarrhythmic Drug Therapy for Suppression of Ventricular Tachycardia in Ischemic Cardiomyopathy: The VANISH2 Trial.
    Am Heart J. 2024 Apr 20:S0002-8703(24)00096-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
32. KEEPANASSERIL A, Pande SN, Suriya Y, Baghel J, et al
    "Comparing the Outcomes of Rheumatic Heart Disease in Pregnancy Complicated with and without Atrial Fibrillation: A Propensity Score Matched Analysis".
    Am Heart J. 2024 Apr 11:S0002-8703(24)00089-9. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
33. TSO JV, Montalvo S, Christle J, Hadley D, et al
    Should ECG criteria for Low QRS voltage (LQRSV) be specific for Sex?
    Am Heart J. 2024;270:117-124.
    PubMed     Abstract available
    
    
    
34. IP JE, Bui H, Camm AJ, Coutu B, et al
    Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
    Am Heart J. 2024;270:55-61.
    PubMed     Abstract available
    
    
    March 2024
35. WU J, Nadarajah R, Nakao YM, Nakao K, et al
    Risk calculator for incident atrial fibrillation across a range of prediction horizons.
    Am Heart J. 2024 Mar 6:S0002-8703(24)00052-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
36. REYNOLDS MR, Passman R, Swindle J, Mohammadi I, et al
    Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries.
    Am Heart J. 2024;269:25-34.
    PubMed     Abstract available
    
    
    
37. RODRIGUEZ MUNOZ D, Ramos Jimenez J, Marco Del Castillo A, Lozano Granero C, et al
    Symptom burden guiding invasive electrophysiological study in paroxysmal supraventricular tachycardia: The believe SVT registry.
    Am Heart J. 2024;269:15-24.
    PubMed     Abstract available
    
    
    February 2024
38. LEE SH, Lee SJ, Heo JH, Ahn SG, et al
    Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
39. JONES ID, Lane DA, Lotto RR, Oxborough D, et al
    Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF) using sensors embedded in the handles of supermarket trolleys: A feasibility study.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00038-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    January 2024
40. CAPPATO R, Mark DB, Silverstein AP, Noseworthy PA, et al
    Regional Differences in Outcomes with Ablation Versus Drug Therapy for Atrial Fibrillation: Results from the CABANA Trial.
    Am Heart J. 2024 Jan 31:S0002-8703(24)00018-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
41. BURNS B, Marschner I, Eggins R, Buscher H, et al
    A randomized trial of expedited intra-arrest transfer versus more extended on-scene resuscitation for refractory out of hospital cardiac arrest: Rationale and design of the EVIDENCE trial.
    Am Heart J. 2024;267:22-32.
    PubMed     Abstract available
    
    
    December 2023
42. KANTHASAMY V, Schilling R, Zongo O, Khan K, et al
    Feasibility of Double-Blinded, Placebo-Controlled Interventional Study for Assessing Catheter Ablation Efficacy in Persistent Atrial Fibrillation: Insights from the ORBITA AF Feasibility study.
    Am Heart J. 2023 Dec 16:S0002-8703(23)00353-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
43. CHEN X, Luo G, Li H, Zheng J, et al
    High prevalence and distinctive clinical features of LMNA-associated atrioventricular block in young patients.
    Am Heart J. 2023 Dec 2:S0002-8703(23)00328-9. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    November 2023
44. SWOJANOWSKY P, Bundis-Dimitrijevic M, Ha CSR, von Korn H, et al
    Rationale and design of the VAST-AF trial: A randomized controlled, blinded, clinical trial to evaluate transcutaneous vagal nerve stimulation for the prevention of persistent atrial fibrillation recurrence.
    Am Heart J. 2023 Nov 30:S0002-8703(23)00325-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
45. CHUI PW, Khokhar A, Gordon KS, Dziura J, et al
    Opioid Prescription and Risk of Atrial Fibrillation in Younger Veterans: Opioid Use and Risk of Atrial Fibrillation.
    Am Heart J. 2023 Nov 8:S0002-8703(23)00310-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    October 2023
46. YAO X, Attia ZI, Behnken EM, Hart MS, et al
    Realtime Diagnosis from Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation with Long Follow-Up (REGAL): Rationale and design of a pragmatic, decentralized, randomized controlled trial.
    Am Heart J. 2023 Oct 30:S0002-8703(23)00298-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    September 2023
47. FLETT A, Cebula A, Nicholas Z, Adam R, et al
    Rationale and study protocol for the BRITISH randomised trial (Using cardiovascular magnetic resonance identified scar as the Benchmark Risk Indication Tool for Implantable cardioverter defibrillators in patients with Non-Ischaemic Cardiomyopathy and
    Am Heart J. 2023 Sep 28:S0002-8703(23)00281-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    August 2023
48. L'HOYES W, Robyns T, Moura-Fereira S, De Meester P, et al
    Effectiveness of the Risk Stratification Proposed by the 2022 European Heart Rhythm Association Expert Consensus Statement on Arrhythmic Mitral Valve Prolapse.
    Am Heart J. 2023 Aug 16:S0002-8703(23)00201-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    July 2023
49. UHE T, Wasser K, Weber-Kruger M, Schabitz WR, et al
    Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism - the Find-AF 2 study - Rationale and design.
    Am Heart J. 2023 Jul 6:S0002-8703(23)00171-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.